Insulin Human is a recombinant protein commercialized by Oramed Pharmaceuticals, with a leading Phase II program in Type 1 Diabetes (Juvenile Diabetes). According to Globaldata, it is involved in 26 clinical trials, of which 23 were completed, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Insulin Human’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Insulin Human is expected to reach an annual total of $136 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Insulin Human Overview

Insulin human (ORMD-0801) is under development for the treatment of NASH, type 1 diabetes and type 2 diabetes. The drug candidate is administered through oral route as a capsule. It is based on POD (Protein Oral Delivery) technology.

Oramed Pharmaceuticals Overview

Oramed Pharmaceuticals (Oramed) is a pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and is administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$2.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 0.3% over FY2020. The operating loss of the company was US$24.2 million in FY2021, compared to an operating loss of US$11.8 million in FY2020. The net loss of the company was US$22.2 million in FY2021, compared to a net loss of US$11.5 million in FY2020. The company reported revenues of US$0.7 million for the third quarter ended September 2022, an increase of 1.2% over the previous quarter.

For a complete picture of Insulin Human’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.